These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 12626282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P, Anunnatsiri S, Mootsikapun P, Kiertiburanakul S, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Ruxrungtham K, Study Team.
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [Abstract] [Full Text] [Related]

  • 5. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 6. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM, SPIRAL Study Group.
    AIDS; 2010 Jul 17; 24(11):1697-707. PubMed ID: 20467288
    [Abstract] [Full Text] [Related]

  • 7. Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients.
    Youle M.
    J Antimicrob Chemother; 2007 Dec 17; 60(6):1195-205. PubMed ID: 17890281
    [Abstract] [Full Text] [Related]

  • 8. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS.
    HIV Med; 2006 Jul 17; 7(5):311-6. PubMed ID: 16945076
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
    Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, Bernstein B, Rode R, Sun E.
    Antivir Ther; 2002 Sep 17; 7(3):165-74. PubMed ID: 12487383
    [Abstract] [Full Text] [Related]

  • 11. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
    Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J, TRIAD Study Group.
    J Antimicrob Chemother; 2009 Aug 17; 64(2):398-410. PubMed ID: 19515730
    [Abstract] [Full Text] [Related]

  • 12. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
    Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA.
    AIDS; 2009 Jan 28; 23(3):279-91. PubMed ID: 19114854
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A review of low-dose ritonavir in protease inhibitor combination therapy.
    Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW.
    Clin Infect Dis; 2003 Jun 15; 36(12):1585-92. PubMed ID: 12802760
    [Abstract] [Full Text] [Related]

  • 17. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 15; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.